This article was originally published in The Gray Sheet
Executive SummaryHybrid Capture II test will be available in May following FDA clearance of the test as an adjunct to Pap smear screening, the firm announces March 19. Digene estimates the U.S. market for borderline Pap smear testing at $70 mil
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.